This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysExplore ContentEventsMaterialsVideosContact

Menu

Close

HomeAboutAboutHow TRUMENBA WorksTru Patient StoriesAre Your Patients Protected?CDC RecommendationsDosingEfficacy & SafetyEfficacy & SafetySafety Profile and TolerabilityImmunogenicity & PersistenceSupport & OrderSupport & OrderEventsMaterialsVideosWelcome to TruSupportOrdering & InventoryCoverage & ReimbursementPatient Adherence
Prescribing InformationIndicationMedical Information
Dosing and CoadministrationOnly TRUMENBA demonstrates confirmed evidence of diverse MenB strain protection with a 2-dose schedule of 0 and 6 months1*†‡

Not actual patients. For illustrative purposes only.

  • If the second dose is administered earlier than 6 months after the first dose, a third dose should be administered at least 4 months after the second dose1

The Advisory Committee on Immunization Practices (ACIP) recommends the 2 doses for persons aged 16 through 23 years who are not at increased risk for meningococcal disease, based on shared clinical decision-making.2

 The 0-, 6-month dosing schedule of TRUMENBA:
•   Proven to provide the maximum diverse MenB strain protection vs 0-, 2-month and 0-, 4-month schedules studied in TRUMENBA clinical trials1,3†

•   Offers a schedule of 0 and 6 months, similar to other adolescent vaccines, including HPV and HepA, which are associated with higher rates of adherence4,5

•   Adolescents and young adults return to their doctor after an average of 6-8 months, which may provide an opportunity to6,7§:
- Discuss preventive health 

- Conduct mental health screenings

- Achieve series completion for vaccines that align with this schedule

ACIP recommends the 3-dose schedule for persons aged ≥10 years who are in a MenB outbreak situation or at increased risk for meningococcal disease.2

These persons include those with persistent complement component deficiencies, those with anatomic or functional asplenia, or microbiologists routinely exposed to isolates of Neisseria meningitidis.1,2

TRUMENBA provides confirmed cross-reactivity against 14 diverse strains that are representative of prevalent MenB strains.1When compared with 0-, 2-month and 0-, 4-month schedules of TRUMENBA. The 0-, 2- and 0-, 4-month schedules did not provide protection against diverse strains of MenB.3The Advisory Committee on Immunization Practices (ACIP) recommends 2 doses for persons aged 16 through 23 years who are not at increased risk of meningococcal disease, based on shared clinical decision-making. ACIP recommends 3 doses (0, 1-2, 6 months) for persons aged 2-10 years who are at increased risk of meningococcal disease or in a MenB outbreak, to provide earlier protection and maximize short-term immunogenicity. Persons at increased risk include those with persistent complement component deficiencies, those with anatomic or functional asplenia, and microbiologists routinely exposed to isolates of Neisseria meningitidis.2Data from a March 2017 US survey of 593 young adults aged 16-21 years.6The choice of dosing schedule may depend on the risk of exposure and the patient’s susceptibility to meningococcal serogroup B disease.1Including patients with inherited or chronic deficiencies in C3, C5-9, properdin, factor D, or factor H, or who are taking eculizumab (Soliris®; Alexion Pharmaceuticals, Inc.).1Only TRUMENBA has been studied concomitantly with 3 other adolescent vaccines1,2
  • Concomitant administration did not significantly increase local reactions or systemic events compared with TRUMENBA alone8,9
The immunogenicity of concomitantly administered TRUMENBA with HPV4, MenACWY, and Tdap vaccines was evaluated in adolescents.1,2
  • The noninferiority criteria were met for all immunogenicity endpoints for MenB strains and MenACWY and Tdap antigens, as well as HPV antigens except HPV-181
  • Seroconversion for all 4 HPV antigens was achieved by ≥99% of subjects in the groups that received HPV4 (secondary endpoint)8

Data are not available to assess the safety and immunogenicity of concomitant administration of TRUMENBA with other routine adolescent vaccines.1​​​​​​

fHbp=factor H binding protein; HepA=hepatitis A; HPV4=quadrivalent human papillomavirus vaccine; HPV=human papillomavirus; MenACWY=quadrivalent (serogroups A, C, W, Y) meningococcal conjugate vaccine; MenB=serogroup B meningococcal disease; Tdap=tetanus, diphtheria, and pertussis vaccine.TitleContact your Pfizer Sales Representative or call a Vaccine Specialist at 1-800-666-7248.References:1. TRUMENBA [package insert]. Philadelphia, PA: Pfizer Inc.; 2021. 2. Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal vaccination: recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep. 2020;69(9):1-41. 3. McDaniel A, Dempsey A, Srivastava A. A physician's guide to the 2-dose schedule of MenB-FHbp vaccine. Hum Vaccin Immunother. 2019;15(11):2729-2737. 4. Packnett ER, Zimmerman NM, Kim G, et al. A real-world claims data analysis of meningococcal serogroup B vaccine series completion and potential missed opportunities in the United States. Pediatr Infect Dis J. 2022;41(4):e158-e165. 5. Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices. Recommended child and adolescent immunization schedule for ages 18 years or younger, United States, 2023. Centers for Disease Control and Prevention website. Updated September 27, 2023. Accessed November 6, 2023. https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf. 6. QuintilesIMS primary research market study, 2017. 7. Centers for Disease Control and Prevention. Teen health services and one-on-one time with a healthcare provider: an infobrief for parents. Centers for Disease Control and Prevention website. December 2016. https://www.cdc.gov/healthyyouth/healthservices/pdf OneonOnetime_FactSheet.pdf. 8. Senders S, Bhuyan P, Jiang Q, et al. Immunogenicity, tolerability and safety in adolescents of bivalent rLP2086, a meningococcal serogroup B vaccine, coadministered with quadrivalent human papilloma virus vaccine. Pediatr Infect Dis J. 2016;35(5):548-554. 9. Muse D, Christensen S, Bhuyan P, et al. A phase 2, randomized, active-controlled, observer-blinded study to assess the immunogenicity, tolerability and safety of bivalent rLP2086, a meningococcal serogroup B vaccine, coadministered with tetanus, diphtheria and acellular pertussis vaccine and serogroup A, C, Y and W-135 meningococcal conjugate vaccine in healthy US adolescents. Pediatr Infect Dis J. 2016;35(6):673-682. 10. Tully J, Viner RM, Coen PG, et al. Risk and protective factors for meningococcal disease in adolescents: matched cohort study. BMJ. 2006;332(7539):445-450. 11. Centers for Disease Control and Prevention. Meningococcal disease. Centers for Disease Control and Prevention website. http://www.cdc.gov/meningococcal/index.html. Updated January 21, 2020. Accessed April 1, 2021. 12. Dwilow R, Fanella S. Invasive meningococcal disease in the 21st century—an update for the clinician. Curr Neurol Neurosci Rep. 2015;15(2):1-9. 13. Balmer P, Burman C, Serra L, York LJ. Impact of meningococcal vaccination on carriage and disease transmission: a review of the literature. Hum Vaccin Immunother. 2018;14(5):1118-1130. Pfizer TruSupport
  • Ordering options
  • Patient coverage confirmation
  • Essential tools
  • Resources for your practice
 Find out about TruSupportLoading
Why adolescents and young adults?

Typical adolescent and young adult behaviors increase MenB risk.10-13

Learn more about MenB
Loading
Pfizer TruSupport
  • Ordering options
  • Patient coverage confirmation
  • Essential tools
  • Resources for your practice
 Find out about TruSupportLoading
 The science behind TRUMENBA

Only TRUMENBA targets both subfamilies, A and B, of fHbp.1

 See the scienceLoading

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2024 Pfizer Inc. All rights reserved.

PP-TRU-USA-3171
You are now leaving Pfizer

You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.

PP-MCL-USA-0367

INDICATION
  • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
Important Safety Information
  • Severe allergic reaction (eg, anaphylaxis) to any component of Trumenba is a contraindication
  • Some individuals with altered immunocompetence may have reduced immune responses to Trumenba
  • Persons with certain complement deficiencies and persons receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis serogroup B even if they develop antibodies following vaccination with Trumenba
  • Vaccination with Trumenba may not protect all vaccine recipients against N meningitidis serogroup B infections
  • Syncope (fainting) can occur in association with administration of injectable vaccines, including Trumenba. Procedures should be in place to avoid injury from fainting
  • In clinical studies, the most common solicited adverse reactions in adolescents and young adults were pain at injection site (≥85%), fatigue (≥60%), headache (≥55%), and muscle pain (≥35%) 
  • Data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series
  • Safety and effectiveness have not been established in pregnant women
Indication
  • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
Please see full Prescribing Information.